TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04444609

Intervention type: OTHER
Intervention: Blood tests sputum, nasal lavage and brushing
Description: Venesection, sputum nasal lavage and brushing if appropriate

Intervention type: OTHER
Intervention: Blood tests sputum, nasal lavage and brushing
Description: Venesection, sputum nasal lavage and brushing if appropriate

Intervention type: OTHER
Intervention: Blood tests sputum, nasal lavage and brushing
Description: Venesection, sputum nasal lavage and brushing if appropriate

Intervention type: OTHER
Intervention: Blood tests sputum, nasal lavage and brushing
Description: Venesection, sputum nasal lavage and brushing if appropriate
Study: NCT04863755

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DASH
Description: Patients receive DASH diet orientation and recommended to maintain their usual physical activity

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DASHPED
Description: Patients receive DASH diet orientation and recommended to increase their usual activity with the use of a pedometer
Study: NCT01048723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Patients were instructed to take RAD001 in the morning, at the same time each day.
Study: NCT03266991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: Treatment with weekly rifapentine and isoniazid as Directly Observed Therapy in 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Treatment with daily isoniazid in 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Treatment with daily isoniazid in 6 months
Study: NCT01103609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral tablet od on Day 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Warfarin
Description: Oral tablet od on Day 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet bd, stepwise increased

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral tablet bd, stepwise increased
Study: NCT02213393

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein enriched products
Description: The intervention group receives CwC protein enriched products. After discharge the intervention group receives CwC products delivered at home for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual menu
Description: The control group receives the usual menu, which is energy and protein rich in this elderly patient group. After discharge the control group receives regular products, no protein enrichment, at home for 12 weeks.
Study: NCT03630809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2 DC1 Vaccine
Description: Ultrasound (US) guided intranodal delivered vaccines will be administered at each participating site by a radiologist experienced in ultrasound guided procedures along with the principal investigator or his/her designee. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1 right and 1 left normal groin lymph nodes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2 DC1 Vaccine
Description: Ultrasound (US) guided intranodal delivered vaccines will be administered at each participating site by a radiologist experienced in ultrasound guided procedures along with the principal investigator or his/her designee. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1 right and 1 left normal groin lymph nodes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HER2 DC1 Vaccine
Description: Ultrasound (US) guided intranodal delivered vaccines will be administered at each participating site by a radiologist experienced in ultrasound guided procedures along with the principal investigator or his/her designee. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1 right and 1 left normal groin lymph nodes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HER2 DC1 Vaccine
Description: Ultrasound (US) guided intranodal delivered vaccines will be administered at each participating site by a radiologist experienced in ultrasound guided procedures along with the principal investigator or his/her designee. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1 right and 1 left normal groin lymph nodes.
Study: NCT03145168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Target Mean Arterial Pressure
Description: High target group (80-85 mm of Hg).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Target Mean Arterial Pressure
Description: Low target MAP group (60-65mm Hg).
Study: NCT03760146

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20vPnC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20vPnC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20vPnC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC
Description: Pneumococcal conjugate vaccine
Study: NCT02400268

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14 days course of antibiotic treatment
Description: Standard antibiotic treatment approved for enterobacteraciae infections
Study: NCT02422550

Intervention type: DEVICE
Intervention: MRI or CT
Description: Participants enrolled on this protocol may undergo multiple MRI or CT examinations periodically over the course of their treatment and follow-up if they are participating in a development project related to tumor response assessment. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
Study: NCT00202267

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Four-layer Bandage (Elastomeric)
Description: Precise components of the four-layer system depend on the circumference of the ankle. All the bandages are discarded after a single use, usually one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short-stretch Bandage (Non-elastomeric)
Description: These bandages are applied in a figure-eight technique; two bandages are applied at full extension in opposite directions up the leg (i.e., clockwise and counter clockwise). The participant will wash the short-stretch wherever possible and reused. The number of bandages supplied to each patient will be recorded on the visit record.
Study: NCT02757651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide
Description: Hydrogen Peroxide
Study: NCT03760146

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal polysaccharide vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo
Study: NCT02874742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Cycles 1 through 6: lenalidomide 25 (milligram) mg orally on Days 1 through 14 and each cycle is of 21-days followed by maintenance treatment with lenalidomide 10 mg on days 1-21 throughout each 28-day cycle on Cycles 7 through 9. Beginning at Cycle 10, the lenalidomide dose will be increased to 15 mg unless there is a tolerability concern.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Cycles 1 through 6: lenalidomide 25 (milligram) mg orally on Days 1 through 14 and each cycle is of 21-days followed by maintenance treatment with lenalidomide 10 mg on days 1-21 throughout each 28-day cycle on Cycles 7 through 9. Beginning at Cycle 10, the lenalidomide dose will be increased to 15 mg unless there is a tolerability concern.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m\^2 subcutaneously on Days 1, 4, 8, and 11 during Cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m\^2 subcutaneously on Days 1, 4, 8, and 11 during Cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg orally every week (20 mg on Days 1, 2, 8, 9, 15, and 16).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg orally every week (20 mg on Days 1, 2, 8, 9, 15, and 16).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly during induction treatment (Days 1, 8, and 15 of Cycles 1 through 4), and every 3 weeks during consolidation treatment (Day 1 of Cycles 5 and 6), followed by maintenance treatment with daratumumab every 4 or 8 weeks.
Study: NCT03930446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol. Women will receive a reduced dose (0.68 g/kg) to account for sex differences in total body water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo beverage will consist of the cranberry or orange juice plus 1% alcohol added as a taste mask. All beverages will be sprayed with an alcoholic mist to provide a strong alcoholic scent.
Study: NCT04252755

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EEG Neurofeedback
Description: Participants will undergo a baseline (pre) session, then be scheduled for 8 sessions of NFB, and finish with another session (post) after completion of all NFB sessions.
Study: NCT03295708

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil capsule
Description: N-3 PUFAs is a kind of essential fatty acid,however the formation is too slow. Studies show that intakes of N-3 PUFAs is associated with MDD.It have to be got from food like deep-sea fishes. EPA and DHA are crucial for the body.Although studies have shown that reduced N-3 PUFAs were correlated with MDD, and patients with an elevated rate of N-6 PUFAs /N-3 PUFAs or a low level of DHA may be at higher odds for suicide. Trials on whether N-3 PUFAs is effective in the treatment of MDD is still controversial, which might be affected by several factors, such as dose, duration etc.. Now there is no large-scale randomized controlled clinical trial in determining the effects of N-3 PUFAs add-on in treatment of MDD.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: soybean oil capsule
Description: placebo capsule
Study: NCT00665977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thermosmart & placebo
Description: a Fisher \& Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Device & Nasacort
Description: Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher \& Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Arm
Description: To enter into the single-blind placebo phase, subjects will be setup with a Fisher \& Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily.
Study: NCT01793727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope videolaryngoscope
Study: NCT01359254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is given through the vein daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is given through the vein daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin (ATG)
Description: ATG is given every other day for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin (ATG)
Description: ATG is given every other day for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan is given daily for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI is given twice on the last day.
Study: NCT00265512

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Case Monitoring
Description: Telephone Case Monitoring involves telephone delivery of continuing care treatment post intensive outpatient SUD treatment. It includes brief weekly phone calls with a counselor for up to 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuing Care as Usual
Description: Continuing Care as Usual will include standard group outpatient SUD treatment.
Study: NCT04390594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesilate
Description: Nafamostat mesilate continuous intravenous injection. Daily dose ranging between 0.1 mg/kg/h and 0.2 mg/kg/h, based on the severity and underlying disease of the clinical trial participant.~Administration for 10-14 days based on the severity and underlying disease of the clinical trial participant
Study: NCT03637803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRx0518
Description: MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Description: Pembrolizumab is a potent humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD1) receptor , thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). The study dosing regimen is 200mg (two 4ml vials of 25mg/ml solution) for IV infusion once every three weeks.
Study: NCT02338765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Physical Activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth Physical Activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy-partnered exercise
Study: NCT03686410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Therapeutic Educational Intervention
Description: The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut.
Study: NCT01828892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy exploration and glue application
Description: A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy exploration and glue application
Description: A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endoscopy exploration
Description: A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization.
Study: NCT02400593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Workshop
Description: Six weeks of formal instruction in Lovingkindness or Mindfulness meditation.
Study: NCT01828892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)
Description: Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)
Description: Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)
Description: Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition support
Description: Nutritional replacement and bowel rest via enteral or parenteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Nutrition support
Description: Nutritional replacement and bowel rest via enteral or parenteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition support
Description: Nutritional replacement and bowel rest via enteral or parenteral nutrition
Study: NCT01457885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine/Busulfan x 4
Description: * Clofarabine IV dose level: 40 mg/m2/day x 5 days~* Busulfan IV dose level: 3.2 mg/kg daily x 4 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplant
Description: Peripheral blood stem cell transplant, after pre-conditioning drug treatment
Study: NCT04668950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Up to 200mg per day (2 capsules per day) as tolerated, for approximately 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will take 2 capsules per day as tolerated for approximately 15 days
Study: NCT01328860

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow progenitor cells (BMPC) autologous transplantation
Description: Not more than 5ml/kg bone marrow will be collected under anesthesia; after the bone marrow has been processed, about 6-8 hours after bone marrow aspiration, subjects will receive the cells via intra-venous (in the vein) infusion and will be monitored for 24 hours for any adverse events.
Study: NCT02983383

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block group (Group T)
Description: At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle (Stimuplex Ultra 22G, 100mm, B.Braun, Germany) tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: Patients in Group P will have adjuvant added to spinal anesthesia (25 G, Quincke spinal anesthesia needle, Egemen,Turkey).